Term
|
Definition
| avoid concomitant use APAP or COX-II if possible |
|
|
Term
|
Definition
| Avoid concomitant use; decrease warfarin dose by 50% pre and 1 wk post |
|
|
Term
| warfarin and macrolides (especially erythromycin) |
|
Definition
| interaction may be delayed; use other category, clarithromycin or azithromycin |
|
|
Term
|
Definition
| use other categor; evidence strong for cipro, levo, norflxacin, enoxacin and ofloxacin |
|
|
Term
|
Definition
| draw potassium levels prior to ACE initiation |
|
|
Term
| GI irritation and erosion, decreased platelet adhesion |
|
Definition
|
|
Term
| unknown; infection and inflammation promotes the effect of warf, may be secondatry to decrease warf degradation in the gut |
|
Definition
|
|
Term
| metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
| warfarin and macrolides (especially erythromycin) |
|
|
Term
| metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
|
|
Term
| CYP2C9 inhibitor which increases levels of S-warfarin |
|
Definition
|
|
Term
| unknown; warf metabolism inhibited early effect and late effect (2-3) weeks warf metab might be induced..lack of effect |
|
Definition
|
|
Term
| ACEI → ↓ aldosterone → ↓ K+ excretion |
|
Definition
|
|
Term
| Additive K+ sparing effects |
|
Definition
|
|
Term
|
Definition
| Draw K+ level prior to starting spironolactone |
|
|
Term
|
Definition
| avoid concomitant use APAP or COX-II if possible |
|
|
Term
|
Definition
| Avoid concomitant use; decrease warfarin dose by 50% pre and 1 wk post |
|
|
Term
| warfarin and macrolides (especially erythromycin) |
|
Definition
| interaction may be delayed; use other category, clarithromycin or azithromycin |
|
|
Term
|
Definition
| use other categor; evidence strong for cipro, levo, norflxacin, enoxacin and ofloxacin |
|
|
Term
|
Definition
| draw potassium levels prior to ACE initiation |
|
|
Term
| GI irritation and erosion, decreased platelet adhesion |
|
Definition
|
|
Term
| unknown; infection and inflammation promotes the effect of warf, may be secondatry to decrease warf degradation in the gut |
|
Definition
|
|
Term
| metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
| warfarin and macrolides (especially erythromycin) |
|
|
Term
| metabolic inhibition; secondary to decreased vit K production by gut flora, may also be inflammation/ infection factor |
|
Definition
|
|
Term
| CYP2C9 inhibitor which increases levels of S-warfarin |
|
Definition
|
|
Term
| unknown; warf metabolism inhibited early effect and late effect (2-3) weeks warf metab might be induced..lack of effect |
|
Definition
|
|
Term
| ACEI → ↓ aldosterone → ↓ K+ excretion |
|
Definition
|
|
Term
| Additive K+ sparing effects |
|
Definition
|
|
Term
|
Definition
| Draw K+ level prior to starting spironolactone |
|
|
Term
|
Definition
| check baseline dig level, decrease dig dose by 50% |
|
|
Term
↓ digoxin clearance
Possible additive effect on SA node? |
|
Definition
|
|
Term
|
Definition
| check baseline dig level, consider dig dose reduction |
|
|
Term
| Synergistic effect leading to bradycardia and heart block; decreased dig clearance |
|
Definition
|
|
Term
| Theophylline + Quinolones |
|
Definition
| check baseline theophylline levels, avoid enoxacin and cipro (30-40% decrease in clearance) |
|
|
Term
| ↓ theophylline Cl- hepatic metabolism inhibited by quinolones |
|
Definition
| Theophylline + Quinolones |
|
|
